A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation.

In agreement with the findings from dedicated PK studies of rivaroxaban ( Kubitza et al., 2005a ; Zhao et al., 2009 ) and, as expected, the limited aqueous solubility of Biopharmaceutical Classification System class II substance ( Kushwah et al., 2021 ), the dosage had a highly significant effect on F 1 .

also in 132,142 other papers

in patients with CrCL 30–49 ml/min demonstrated a strong trend for a decrease in the rate of stroke/systemic embolism with rivaroxaban versus warfarin and a good safety profile.

also in 5,725 other papers

Most patient models for rivaroxaban were one-compartment models due to the sparsely sampled PK data, which might cause a slight trend toward an underestimation of C max ( Willmann et al., 2018 ).

also in 4,078 other papers